Evidence map›Paper›PMID 25825741›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Gαi1 and Gαi3 regulate macrophage polarization by forming a complex containing CD14 and Gab1.

Xianjing Li, Duowei Wang, Zhen Chen, Ermei Lu, Zhuo Wang, Jingjing Duan, Wei Tian, Yun Wang, Linjun You, Yulian Zou and 10 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Gαi1/3 Is a Novel Regulatory Target for RANKL Signal Transduction and Osteoporosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Target and Cell Therapy for Atherosclerosis and CVD.International journal of molecular sciences · 2023
    Review
  19. Article
  20. SCF/c-Kit-activated signaling and angiogenesis require Gαi1 and Gαi3.International journal of biological sciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 2 countries.

Xianjing LiState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Duowei WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Zhen ChenState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Ermei LuState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Zhuo WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Jingjing DuanState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Wei TianState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Yun WangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Linjun YouState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Yulian ZouState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Yan ChengState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Qingyi ZhuDepartment of Urology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing 210029, China;
Xiaojian WanDepartment of Anesthesiology and Intensive Care Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China; and.
Tao XiState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China;
Meisheng JiangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
Yuyuan HanDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912
Cong CaoDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912
Lutz BirnbaumerLaboratory of Neurobiology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 yy@cpu.edu.cn birbau1@gmail.com.
Wen-Ming ChuDepartment of Molecular Microbiology and Immunology, Brown University, Providence, RI 02912
Yong YangState Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China; yy@cpu.edu.cn birbau1@gmail.com.
State Key Laboratory of Natural MedicineChina Pharmaceutical University · CNBrown University · USCancer Center of Hawaii · USChanghai Hospital · CNJiangsu Province Hospital · CNNational Institutes of Health · USUniversity of California, Los Angeles · US

Funding

Transmembrane Signaling MechanismsZ01ES101643 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI BIRNBAUMER, LUTZ · 2003 to 2008
$5.1M
Mechansim of activation of innate immunity by ISS-DNAR01AI054128 · NIAID · UNIVERSITY OF HAWAII AT MANOA · PI CHU, WEN-MING · 2002 to 2013
$2.7M
Modulation of Insulin Secretion via Go2 G-ProteinR01DK069771 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JIANG, MEISHENG · 2005 to 2009
$1.6M
Intramural NIH HHS Z01 ES101643NIAID NIH HHS R01 AI054128NIDDK NIH HHS R01 DK069771
6 · The paper itself

Abstract

Heterotrimeric G proteins have been implicated in Toll-like receptor 4 (TLR4) signaling in macrophages and endothelial cells. However, whether guanine nucleotide-binding protein G(i) subunit alpha-1 and alpha-3 (Gαi1/3) are required for LPS responses remains unclear, and if so, the underlying mechanisms need to be studied. In this study, we demonstrated that, in response to LPS, Gαi1/3 form complexes containing the pattern recognition receptor (PRR) CD14 and growth factor receptor binding 2 (Grb2)-associated binding protein (Gab1), which are required for activation of PI3K-Akt signaling. Gαi1/3 deficiency decreased LPS-induced TLR4 endocytosis, which was associated with decreased phosphorylation of IFN regulatory factor 3 (IRF3). Gαi1/3 knockdown in bone marrow-derived macrophage cells (Gαi1/3 KD BMDMs) exhibited an M2-like phenotype with significantly suppressed production of TNF-α, IL-6, IL-12, and NO in response to LPS. The altered polarization coincided with decreased Akt activation. Further, Gαi1/3 deficiency caused LPS tolerance in mice. In vitro studies revealed that, in LPS-tolerant macrophages, Gαi1/3 were down-regulated partially by the proteasome pathway. Collectively, the present findings demonstrated that Gαi1/3 can interact with CD14/Gab1, which modulates macrophage polarization in vitro and in vivo.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBlotting, WesternCell Line, TumorCells, CulturedEndocytosisGTP-Binding Protein alpha Subunits, Gi-GoHumansInterleukin-12Interleukin-6Lipopolysaccharide ReceptorsLipopolysaccharidesMacrophagesMacrophages, PeritonealMice, 129 StrainMice, KnockoutAdaptor Proteins, Signal TransducingGab1 protein, mouseGTP-Binding Protein alpha Subunits, Gi-GoInterleukin-12Interleukin-6Lipopolysaccharide ReceptorsLipopolysaccharidesMitogen-Activated Protein KinasesPhosphoproteinsProtein SubunitsToll-Like Receptor 4Tumor Necrosis Factor-alphaendosomeGαi1Gαi3macrophage polarizationToll-like receptor 4

Identifiers

PMID25825741
PMCPMC4403188
OpenAlexW2089695345

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.